<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40230544</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2754-4591</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>Suppl 2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Oxford open digital health</Title><ISOAbbreviation>Oxf Open Digit Health</ISOAbbreviation></Journal><ArticleTitle>Beyond the hype: a call for comprehensive evidence on the economic and health outcomes of digital and data technologies.</ArticleTitle><Pagination><StartPage>ii4</StartPage><EndPage>ii8</EndPage><MedlinePgn>ii4-ii8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/oodh/oqae041</ELocationID><Abstract><AbstractText Label="UNLABELLED">Digital and data technologies are increasingly being implemented to meet a range of global health needs, including strengthening health systems, improving efficiency and advancing universal health coverage. However, there is limited quantitative evidence and few standardized methodologies for analyzing the health impact and cost-effectiveness of digital and data technologies in health systems in low- and middle-income countries. Without such evidence, development partners, patients, civil society and government leaders have a limited basis from which to incentivize, justify and allocate funding for sustained investments in digital and data technologies, which in turn impacts their sustainability. Dedicated funding and planning for such efforts can help decision-makers hold digital health providers accountable and improve the allocation of limited resources.</AbstractText><AbstractText Label="RESUMEN" NlmCategory="RESULTS">Las tecnolog&#xed;as digitales y de datos se est&#xe1;n implementando cada vez m&#xe1;s para satisfacer distintas necesidades de salud a nivel global, incluyendo fortalecer los sistemas de salud, mejorar la eficiencia y propiciar la cobertura universal de salud. Sin embargo, hay evidencia cuantitativa limitada y pocas metodolog&#xed;as estandarizadas para analizar el efecto en la salud y la efectividad de costos de las tecnolog&#xed;as digitales y de datos en los sistemas de salud en pa&#xed;ses de ingresos bajos y medios. Sin tal evidencia, los socios de desarrollo, los pacientes, la sociedad civil y los l&#xed;deres gubernamentales tienen una base limitada para crear incentivos, justificar y asignar fondos para inversiones continuas en tecnolog&#xed;as digitales y de datos, lo cual a su vez afecta su sustentabilidad. La asignaci&#xf3;n de fondos y la planificaci&#xf3;n dirigidas para tales esfuerzos pueden ayudar a las personas encargadas de tomar decisiones a confiar la responsabilidad a los proveedores de salud digital y a mejorar la asignaci&#xf3;n de recursos limitados.</AbstractText><AbstractText Label="RESUMO" NlmCategory="UNASSIGNED">As tecnologias digitais e de dados est&#xe3;o a ser cada vez mais implementadas para responder a uma s&#xe9;rie de necessidades globais de sa&#xfa;de, incluindo o refor&#xe7;o dos sistemas de sa&#xfa;de, a melhoria da efici&#xea;ncia e o avan&#xe7;o da cobertura universal de sa&#xfa;de. No entanto, existem poucos dados quantitativos e poucas metodologias normalizadas para analisar o impacto na sa&#xfa;de e a rela&#xe7;&#xe3;o custo-efic&#xe1;cia das tecnologias digitais e de dados nos sistemas de sa&#xfa;de dos pa&#xed;ses de baixo e m&#xe9;dio rendimento. Sem essas provas, os parceiros de desenvolvimento, os doentes, a sociedade civil e os l&#xed;deres governamentais t&#xea;m uma base limitada para incentivar, justificar e atribuir financiamento para investimentos sustentados em tecnologias digitais e de dados, o que, por sua vez, afeta a sua sustentabilidade. O financiamento e o planeamento dedicados a esses esfor&#xe7;os podem ajudar os decisores a responsabilizar os fornecedores de sa&#xfa;de digital e a melhorar a afeta&#xe7;&#xe3;o de recursos limitados.</AbstractText><AbstractText Label="R&#xc9;SUM&#xc9;" NlmCategory="UNASSIGNED">Les technologies num&#xe9;riques et de donn&#xe9;es sont de plus en plus utilis&#xe9;es pour r&#xe9;pondre &#xe0; une s&#xe9;rie de besoins de sant&#xe9; mondiaux, notamment le renforcement des syst&#xe8;mes de sant&#xe9;, l'am&#xe9;lioration de l'efficacit&#xe9;, et la promotion de la couverture sanitaire universelle. Cependant, il existe peu de donn&#xe9;es quantitatives et peu de m&#xe9;thodologies standardis&#xe9;es pour analyser l'impact sur la sant&#xe9; et la rentabilit&#xe9; des technologies num&#xe9;riques et de donn&#xe9;es dans les syst&#xe8;mes de sant&#xe9; des pays &#xe0; revenu faible et interm&#xe9;diaire. Sans ces preuves, les partenaires de d&#xe9;veloppement, les patients, la soci&#xe9;t&#xe9; civile et les dirigeants gouvernementaux disposent d'une base limit&#xe9;e pour encourager, justifier et&#xa0;allouer des fonds aux investissements durables dans les technologies num&#xe9;riques et de donn&#xe9;es, ce qui a &#xe0; son tour un impact sur leur durabilit&#xe9;. Un financement et une planification d&#xe9;di&#xe9;s &#xe0; ces efforts peuvent aider les d&#xe9;cideurs &#xe0; demander des comptes aux prestataires de sant&#xe9; num&#xe9;rique et &#xe0; am&#xe9;liorer l'allocation de ressources limit&#xe9;es.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kallen</LastName><ForeName>Laura Edison</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Center for Digital and Data Excellence, PATH, 455 Massachusetts Avenue NW, Suite 1000, Washington, DC 20001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoden</LastName><ForeName>Sarah Skye</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Health Policy and Management, Harvard University, 677 Huntington Avenue, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrick</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Market Dynamics, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemma</LastName><ForeName>Wuleta</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Wollo University, 1145 Dessie, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorgens</LastName><ForeName>Marelize</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Human Development Practice Group, The World Bank, 1818 H Street, Washington, DC 20433, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Oxf Open Digit Health</MedlineTA><NlmUniqueID>9918716088606676</NlmUniqueID><ISSNLinking>2754-4591</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cost-effectiveness</Keyword><Keyword MajorTopicYN="N">digital health interventions</Keyword><Keyword MajorTopicYN="N">evidence</Keyword><Keyword MajorTopicYN="N">financing</Keyword><Keyword MajorTopicYN="N">health outcomes</Keyword><Keyword MajorTopicYN="N">impact</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>15</Day><Hour>4</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40230544</ArticleId><ArticleId IdType="pmc">PMC11936320</ArticleId><ArticleId IdType="doi">10.1093/oodh/oqae041</ArticleId><ArticleId IdType="pii">oqae041</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . Global Strategy on Digital Health 2020-2025. Geneva, Switzerland: World Health Organization, 2021. https://iris.who.int/bitstream/handle/10665/344249/9789240020924-eng.pdf.</Citation></Reference><Reference><Citation>World Health Organization . WHO Guideline: Recommendations on Digital Interventions for Health System Strengthening. Geneva, Switzerland: World Health Organization, 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31162915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolasa K, Kozinski G. How to value digital health interventions? A systematic literature review. Int J Environ Res Public Health 2020;17:2119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7143608</ArticleId><ArticleId IdType="pubmed">32209988</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufts Medical Center . Cost-effectiveness analysis registry. https://cear.tuftsmedicalcenter.org/ (30 July 2024, date last accessed).</Citation></Reference><Reference><Citation>Disease Control Priorities Project . About the Project. London, United Kingdom: London School of Hygiene and Tropical Medicine. https://www.dcp-3.org/about-project (30 July 2024, date last accessed).</Citation></Reference><Reference><Citation>Ministry of Public Health, Thailand . Health Intervention and Technology Assessment Program (HITAP). Nonthaburi, Thailand: Ministry of Public Health. https://www.hitap.net/en/ (30 July 2024, date last accessed).</Citation></Reference><Reference><Citation>Department of Health and Social Care, UK. National Institute for Health and Care Excellence (NICE). Manchester, United Kingdom: National Institute for Health and Care Excellence. https://www.nice.org.uk/ (30 July 2024, date last accessed).</Citation></Reference><Reference><Citation>Transform Health . Investing in Digital Health. Geneva, Switzerland: Transform Health. https://transformhealthcoalition.org/investing-in-digital-health/ (30 July 2024, date last accessed).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38100620</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Aggressive Angiomyxoma of the Pelvis: 35-Year Experience.</ArticleTitle><Pagination><StartPage>514</StartPage><EndPage>522</EndPage><MedlinePgn>514-522</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003152</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Aggressive angiomyxoma is a very rare mesenchymal tumor most commonly found in the pelvic and perineal regions. Although many are estrogen and progesterone hormone receptor positive, the pathogenesis is unknown. Due to its rarity, there is a paucity of literature relating to this pathology. This article presents a case series on the management of aggressive angiomyxoma of the pelvis.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To present a 35-year experience managing aggressive angiomyxoma of the pelvis.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This was a retrospective single-system analysis.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">This study was conducted at a quaternary referral academic health care system.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All patients treated for aggressive angiomyxoma of the pelvis.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">All patients underwent surgical or medical management of their disease.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary outcomes were disease recurrence and mortality. Secondary outcomes included risk factors for recurrence.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 32 patients (94% women) were identified with a median follow-up of 65 months. Thirty patients (94%) underwent operative resection and 2 patients were treated solely with medical management. Fifteen achieved an R0 resection (negative microscopic margins) at the index operation, of which 4 (27%) experienced tumor recurrence. There were no mortalities. No risk factors for disease recurrence were identified.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Limitations to our study include its nonrandomized retrospective nature, single health care system experience, and small patient sample size.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Aggressive angiomyxoma is a rare, slow-growing tumor with locally invasive features and a high potential for recurrence even after resection with negative margins. Imaging modalities such as CT or MRI should be obtained to aid in diagnosis and surgical planning. Workup should be paired with preoperative biopsy and testing for hormone receptor status, which can increase diagnostic accuracy and guide medical treatment. Close posttreatment surveillance is imperative to detect recurrence. See Video Abstract .</AbstractText><AbstractText Label="ANGIOMIXOMA AGRESIVO DE PELVIS EXPERIENCIA DE AOS" NlmCategory="UNASSIGNED">ANTECEDENTES:El angiomixoma agresivo es un tumor mesenquimal muy raro que se encuentra m&#xe1;s com&#xfa;nmente en las regiones p&#xe9;lvica y perineal. Aunque muchos son positivos para los receptores hormonales como el estr&#xf3;geno y la progesterona, la patog&#xe9;nesis es a&#xfa;n desconocida. Debido a su rareza, existe escasa literatura relacionada con esta patolog&#xed;a. Este art&#xed;culo presenta una serie de casos sobre el tratamiento del angiomixoma agresivo de pelvis.OBJETIVO:Presentar una experiencia de 35 a&#xf1;os en el manejo del angiomixoma agresivo de pelvis.DISE&#xd1;O:Este fue un an&#xe1;lisis retrospectivo de sistema &#xfa;nico.AJUSTES:Este estudio se llev&#xf3; a cabo en un sistema de salud acad&#xe9;mico de referencia de nivel cuaternario.PACIENTES:Todos los pacientes tratados por angiomixoma agresivo de pelvis.INTERVENCIONES:Todos los pacientes se sometieron a tratamiento quir&#xfa;rgico y/o m&#xe9;dico de su enfermedad.PRINCIPALES MEDIDAS DE RESULTADO:Los resultados primarios fueron la recurrencia de la enfermedad y la mortalidad. Los resultados secundarios incluyeron factores de riesgo de recurrencia.RESULTADOS:Se identificaron un total de 32 pacientes (94% mujeres) con una mediana de seguimiento de 65 meses. Treinta (94%) fueron sometidos a resecci&#xf3;n quir&#xfa;rgica y dos fueron tratados &#xfa;nicamente con tratamiento m&#xe9;dico. Quince lograron una resecci&#xf3;n R0 (m&#xe1;rgenes microsc&#xf3;picos negativos) en la operaci&#xf3;n inicial, de los cuales cuatro (27%) experimentaron recurrencia tumoral. No hubo mortalidades. No se identificaron factores de riesgo para la recurrencia de la enfermedad.LIMITACIONES:Las limitaciones de nuestro estudio incluyen su naturaleza retrospectiva no aleatoria, la experiencia de un solo sistema de atenci&#xf3;n m&#xe9;dica y el tama&#xf1;o peque&#xf1;o de la muestra de pacientes.CONCLUSIONES:El angiomixoma agresivo es un tumor raro, de crecimiento lento, con caracter&#xed;sticas localmente invasivas y un alto potencial de recurrencia incluso despu&#xe9;s de una resecci&#xf3;n con m&#xe1;rgenes negativos. Se deben obtener modalidades de im&#xe1;genes como CT y/o MRI para la ayuda diagn&#xf3;stica y la planificaci&#xf3;n quir&#xfa;rgica. El estudio debe combinarse con una biopsia preoperatoria y pruebas del estado de los receptores hormonales, que pueden aumentar la precisi&#xf3;n del diagn&#xf3;stico y guiar el tratamiento m&#xe9;dico. Es imperativa una estrecha vigilancia posterior al tratamiento para detectar recurrencia. (Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cardenas Lara</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauzon</LastName><ForeName>Justin S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>William R G</ForeName><Initials>WRG</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0003-1390-0019</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010388" MajorTopicYN="Y">Pelvis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010502" MajorTopicYN="N">Perineum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009232" MajorTopicYN="Y">Myxoma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>15</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>15</Day><Hour>14</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38100620</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003152</ArticleId><ArticleId IdType="pii">00003453-202404000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fletcher CDM; World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013.</Citation></Reference><Reference><Citation>Kurman RJ; International Agency for Research on Cancer, World Health Organization. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014.</Citation></Reference><Reference><Citation>Steeper TA, Rosai J. Aggressive angiomyxoma of the female pelvis and perineum report of nine cases of a distinctive type of gynecologic soft-tissue neoplasm. Am J Surg Pathol. 1983;7:463&#x2013;475.</Citation></Reference><Reference><Citation>Sutton BJ, Laudadio J. Aggressive angiomyxoma. Arch Pathol Lab Med. 2012;136:217&#x2013;221.</Citation></Reference><Reference><Citation>Nucci MR. Mesenchymal lesions of the lower genital tract. Surg Pathol Clin. 2009;2:603&#x2013;623.</Citation></Reference><Reference><Citation>Li X, Ye Z. Aggressive angiomyxoma of the pelvis and perineum: a case report and review of the literature. Abdom Imaging. 2011;36:739&#x2013;741.</Citation></Reference><Reference><Citation>Alhabshi SM, Abd Rashid M. Large perineal and gluteal angiomyxoma: the role of diagnostic imaging and literature review. BMJ Case Rep. 2013;2013:bcr2013008680.</Citation></Reference><Reference><Citation>McCluggage WG. A review and update of morphologically bland vulvovaginal mesenchymal lesions. Int J Gynecol Pathol. 2005;24:26&#x2013;38.</Citation></Reference><Reference><Citation>Chen H, Zhao H, Xie Y, Jin M. Clinicopathological features and differential diagnosis of aggressive angiomyxoma of the female pelvis: 5 case reports and literature review. Medicine (Baltimore). 2017;96:e6820.</Citation></Reference><Reference><Citation>Chapel DB, Cipriani NA, Bennett JA. Mesenchymal lesions of the vulva. Semin Diagn Pathol. 2021;38:85&#x2013;98.</Citation></Reference><Reference><Citation>Sun NX, Li W. Aggressive angiomyxoma of the vulva: case report and literature review. J Int Med Res. 2010;38:1547&#x2013;1552.</Citation></Reference><Reference><Citation>Kelley SR. Robotic extralevator excision of a retrorectal giant aggressive angiomyxoma. Obstet Gynecol Sci. 2018;61:693&#x2013;697.</Citation></Reference><Reference><Citation>Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol. 2012;120:595&#x2013;603.</Citation></Reference><Reference><Citation>Zou R, Xu H, Shi Y, Wang J, Wang S, Zhu L. Retrospective analysis of clinicopathological features and prognosis for aggressive angiomyxoma of 27 cases in a tertiary center: a 14-year survey and related literature review. Arch Gynecol Obstet. 2020;302:219&#x2013;229.</Citation></Reference><Reference><Citation>Mochizuki H, Kadowaki K, Shiokawa H, Ishii J, Lee K. [A case of pelvic aggressive angiomyxoma involving urinary bladder]. Nihon Hinyokika Gakkai zasshi. 1999;90:882&#x2013;885.</Citation></Reference><Reference><Citation>Liu M, Zhai TS, Zhao XF, et al. Incidental para-ureteral aggressive angiomyxoma: a rare case report and literature review. BMC Urol. 2020;20:182.</Citation></Reference><Reference><Citation>Ichiyanagi N, Yamada T, Kamata S, et al. [Aggressive angiomyxoma in the scrotum: a case report]. Hinyokika Kiyo. 1999;45:69&#x2013;72.</Citation></Reference><Reference><Citation>Beuran M, Ciubotaru C, Runcanu A, Enache V, Negoi I. Surgical resection of retroperitoneal aggressive angiomyxoma: case report and review of the literature. Cureus. 2017;9:e1485.</Citation></Reference><Reference><Citation>Siassi RM, Papadopoulos T, Matzel KE. Metastasizing aggressive angiomyxoma. N Engl J Med. 1999;341:1772.</Citation></Reference><Reference><Citation>Blandamura S, Cruz J, Faure Vergara L, Machado Puerto I, Ninfo V. Aggressive angiomyxoma: a second case of metastasis with patient&#x2019;s death. Hum Pathol. 2003;34:1072&#x2013;1074.</Citation></Reference><Reference><Citation>Geng J, Cao B, Wang L. Aggressive angiomyxoma: an unusual presentation. Korean J Radiol. 2012;13:90&#x2013;93.</Citation></Reference><Reference><Citation>Wu H, Liu W, Xu H, Wang D, Ouyang A. Aggressive angiomyxoma of the pelvis: a series of four cases and literature review. Eur J Gynaecol Oncol. 2015;36:610&#x2013;614.</Citation></Reference><Reference><Citation>Miguez Gonzalez J, Dominguez Oronoz R, Lozano Arranz P, Calaf Forn F, Barrios Sanchez P, Garcia Jimenez A. Aggressive angiomyxoma: imaging findings in 3 cases with clinicopathological correlation and review of the literature. J Comput Assist Tomogr. 2015;39:914&#x2013;921.</Citation></Reference><Reference><Citation>Wiser A, Korach J, Gotlieb WH, Fridman E, Apter S, Ben-Baruch G. Importance of accurate preoperative diagnosis in the management of aggressive angiomyxoma: report of three cases and review of the literature. Abdom Imaging. 2006;31:383&#x2013;386.</Citation></Reference><Reference><Citation>Faria SC, Elsherif SB, Sagebiel T, et al. Ischiorectal fossa: benign and malignant neoplasms of this &#x201c;ignored&#x201d; radiological anatomical space. Abdom Radiol (NY). 2019;44:1644&#x2013;1674.</Citation></Reference><Reference><Citation>Kasper B, Raut CP, Gronchi A. Desmoid tumors: to treat or not to treat, that is the question. Cancer. 2020;126:5213&#x2013;5221.</Citation></Reference><Reference><Citation>Abarzua-Araya A, Lallas A, Piana S, Longo C, Moscarella E, Argenziano G. Superficial angiomyxoma of the skin. Dermatol Pract Concept. 2016;6:47&#x2013;49.</Citation></Reference><Reference><Citation>Ponce-Olivera RM, Tirado-Sanchez A, Peniche-Castellanos A, Peniche-Rosado J, Mercadillo-Perez P. Myxoid neurofibroma: an unusual presentation. Indian J Dermatol. 2008;53:35&#x2013;36.</Citation></Reference><Reference><Citation>Loubignac F, Bourtoul C, Chapel F. Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance. World J Surg Oncol. 2009;7:42.</Citation></Reference><Reference><Citation>Mandato VD, Santagni S, Cavazza A, Aguzzoli L, Abrate M, La Sala GB. Cellular angiofibroma in women: a review of the literature. Diagn Pathol. 2015;10:114.</Citation></Reference><Reference><Citation>Schoolmeester JK, Fritchie KJ. Genital soft tissue tumors. J Cutan Pathol. 2015;42:441&#x2013;451.</Citation></Reference><Reference><Citation>Dagur G, Gandhi J, Kapadia K, et al. Neoplastic diseases of the spermatic cord: an overview of pathological features, evaluation, and management. Transl Androl Urol. 2017;6:101&#x2013;110.</Citation></Reference><Reference><Citation>Silverman JS, Albukerk J, Tamsen A. Comparison of angiomyofibroblastoma and aggressive angiomyxoma in both sexes: four cases composed of bimodal CD34 and factor XIIIa positive dendritic cell subsets. Pathol Res Pract. 1997;193:673&#x2013;682.</Citation></Reference><Reference><Citation>Rawlinson NJ, West WW, Nelson M, Bridge JA. Aggressive angiomyxoma with t(12;21) and HMGA2 rearrangement: report of a case and review of the literature. Cancer Genet Cytogenet. 2008;181:119&#x2013;124.</Citation></Reference><Reference><Citation>Hess JL. Chromosomal translocations in benign tumors: the HMGI proteins. Am J Clin Pathol. 1998;109:251&#x2013;261.</Citation></Reference><Reference><Citation>McCluggage WG. Recent developments in vulvovaginal pathology. Histopathology. 2009;54:156&#x2013;173.</Citation></Reference><Reference><Citation>Piura B, Shaco-Levy R. Pedunculated aggressive angiomyxoma arising from the vaginal suburethral area: case report and review of literature. Eur J Gynaecol Oncol. 2005;26:568&#x2013;571.</Citation></Reference><Reference><Citation>Chihara Y, Fujimoto K, Takada S, et al. Aggressive angiomyxoma in the scrotum expressing androgen and progesterone receptors. Int J Urol. 2003;10:672&#x2013;675.</Citation></Reference><Reference><Citation>Wang Q, Zhao M, Lin X, Zhong W, Gao Y. Aggressive angiomyxoma of the vulva: intra-operative pathological diagnosis is useful in deciding the scope of surgery and reducing recurrence. Acta Chir Belg. 2012;112:79&#x2013;84.</Citation></Reference><Reference><Citation>Haldar K, Martinek IE, Kehoe S. Aggressive angiomyxoma: a case series and literature review. Eur J Surg Oncol. 2010;36:335&#x2013;339.</Citation></Reference><Reference><Citation>Xu H, Sun P, Xu R, Wang L, Shi Y. Aggressive angiomyxoma in pregnancy: a case report and literature review. J Int Med Res. 2020;48:300060520936414.</Citation></Reference><Reference><Citation>Bagga R, Keepanasseril A, Suri V, Nijhawan R. Aggressive angiomyxoma of the vulva in pregnancy: a case report and review of management options. MedGenMed. 2007;9:16.</Citation></Reference><Reference><Citation>Pannier D, Cordoba A, Ryckewaert T, Robin YM, Penel N. Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis. Crit Rev Oncol Hematol. 2019;143:62&#x2013;66.</Citation></Reference><Reference><Citation>Coppola S, Desai A, Tzanis D, et al. Conservative en bloc surgery for aggressive angiomyxoma achieves good local control: analysis of 14 patients from a single institution. Int J Gynecol Cancer. 2013;23:540&#x2013;545.</Citation></Reference><Reference><Citation>Rhomberg W, Jasarevic Z, Alton R, Kompatscher P, Beer G, Breitfellner G. Aggressive angiomyxoma: irradiation for recurrent disease. Strahlenther Onkol. 2000;176:324&#x2013;326.</Citation></Reference><Reference><Citation>Suleiman M, Duc C, Ritz S, Bieri S. Pelvic excision of large aggressive angiomyxoma in a woman: irradiation for recurrent disease. Int J Gynecol Cancer. 2006;16(suppl 1):356&#x2013;360.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32425708</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-349X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of the American College of Radiology : JACR</Title><ISOAbbreviation>J Am Coll Radiol</ISOAbbreviation></Journal><ArticleTitle>La batalla contra la enfermedad del Coronavirus 2019 (COVID-19): Manejo de Emergencia y Control de Infecciones en un Departamento de Radiolog&#xed;a.</ArticleTitle><Pagination><StartPage>e29</StartPage><EndPage>e36</EndPage><MedlinePgn>e29-e36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacr.2020.05.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1546-1440(20)30529-9</ELocationID><Abstract><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Describir las estrategias, manejo de emergencias y los procedimientos de control de infecciones de nuestro departamento durante el brote de la enfermedad por coronavirus 2019 (COVID-19). M&#xe9;TODOS: Creamos un equipo de manejo de emergencias. El equipo estableci&#xf3; varias medidas: Reconfiguraci&#xf3;n del flujo de trabajo en el departamento de radiolog&#xed;a, distribuci&#xf3;n de material de protecci&#xf3;n personal y adiestramiento del personal, procedimientos para la obtenci&#xf3;n de im&#xe1;genes en pacientes sospechosos o confirmados con COVID-19, as&#xed; como para pacientes sin historial de exposici&#xf3;n o s&#xed;ntomas. Aquellos con sospecha o confirmaci&#xf3;n de COVID-19 fueron escaneados en una unidad dedicada para ello.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Del 21 de enero del 2020 hasta el 9 de marzo del 2020, 3,083 personas con sospecha o confirmaci&#xf3;n de COVID-19 recibieron CT de torax. Incluyendo los ex&#xe1;menes iniciales y repetidos, el n&#xfa;mero total de CT fue 3,340. Como resultado de nuestras medidas de precauci&#xf3;n, ninguno de los miembros del personal del departamento de radiolog&#xed;a fue infectado con COVID-19. CONCLUSI&#xf3;N: Las estrategias de planificaci&#xf3;n y las protecciones adecuadas pueden ayudar a proteger a los pacientes y al personal contra una enfermedad altamente infecciosa. Y a la misma vez ayudar a mantener la capacidad de atender un volumen alto de pacientes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 American College of Radiology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zixing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Departamento de Radiolog&#xed;a, Hospital del Oeste de China, Universidad de Sichuan, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departamento de Radiolog&#xed;a, Hospital del Oeste de China, Universidad de Sichuan, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhenlin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Departamento de Radiolog&#xed;a, Hospital del Oeste de China, Universidad de Sichuan, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weixia</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Departamento de Radiolog&#xed;a, Hospital del Oeste de China, Universidad de Sichuan, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Radiolog&#xed;a, Hospital del Oeste de China, Universidad de Sichuan, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Radiolog&#xed;a, Hospital del Oeste de China, Universidad de Sichuan, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departamento de Radiolog&#xed;a, Hospital del Oeste de China, Universidad de Sichuan, Chengdu, China. Electronic address: songlab_radiology@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Radiol</MedlineTA><NlmUniqueID>101190326</NlmUniqueID><ISSNLinking>1546-1440</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">control de infecciones</Keyword><Keyword MajorTopicYN="N">neumon&#xed;a por el nuevo coronavirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32425708</ArticleId><ArticleId IdType="pmc">PMC7229914</ArticleId><ArticleId IdType="doi">10.1016/j.jacr.2020.05.006</ArticleId><ArticleId IdType="pii">S1546-1440(20)30529-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Health Commission of the People&#x2019;s Republic of China  March 12: Daily briefing on novel coronavirus cases in China. Available at. March 11, 2020. http://en.nhc.gov.cn/2020-03/12/c_77618.htm Published 2020. Accessed.</Citation></Reference><Reference><Citation>World Health Organization. Coronavirus disease  2019 (COVID-19) Situation Report&#x2014;52. Available at. March 11, 2020. https://www.who.int/docs/defaultsource/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrsn.e2bfc9c0_29 Published 2020. Accessed.</Citation></Reference><Reference><Citation>National Health Commission of the People&#x2019;s Republic of China  Latest developments in epidemic control on Feb 15 Available at. http://english.www.gov.cn/news/topnews/202002/16/content_WS5e489cbdc6d0595e03c20d4b.html Published 2020. Accessed March 11, 2020.</Citation></Reference><Reference><Citation>Health Commission of the People&#x2019;s Republic of China. The notification of the trial operation based on the guideline version 6 in the coronavirus disease diagnosis and treatment. Available at: http://www.nhc.gov.cn/xcs/zhengcwj/202002/8334a8326dd94d329df351d7da8aefc2.shtml. Published 2020. Accessed March 11, 2020</Citation></Reference><Reference><Citation>Health Commission of the People&#x2019;s Republic of China  The guideline for pathogens isolated operations in hospital. Available at. March 11, 2020. http://www.nhc.gov.cn/wjw/s9496/200904/40116.shtml Published 2009. Accessed.</Citation></Reference><Reference><Citation>Health Commission of the People&#x2019;s Republic of China  The guideline for prevention and control of hospital acquired infections of airborne pathogens. Available at. March 11, 2020. http://www.nhc.gov.cn/wjw/s9496/201701/7e0e8fc6725843aabba8f841f2f585d2.shtml Published 2017. Accessed.</Citation></Reference><Reference><Citation>Health Commission of the People&#x2019;s Republic of China  The standardization for sterilization techniques in hospital. Available at. March 11, 2020. http://www.nhc.gov.cn/wjw/s9496/201204/54510.shtml Published 2012. Accessed.</Citation></Reference><Reference><Citation>Katona P. Bioterrorism preparedness: generic blueprint for health departments, hospitals, and physicians. Infect Dis Clin Pract (Baltim Md) 2002;11:115&#x2013;122.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>